GLP-1 Peptides Explained: How They Work

The most significant shift in weight management science in a generation has come from a class of compounds built around a single hormone: GLP-1.

Glucagon-Like Peptide-1 is not new. Scientists have known about it since the 1980s. But recent advances in how we can mimic and extend its effects have produced compounds with weight loss outcomes that were previously only achievable through surgery.

Understanding how GLP-1 actually works, not just the marketing version but the genuine biology, will help you make more informed decisions about whether these compounds belong in your health protocol.

What Is GLP-1?

GLP-1 is an incretin hormone, meaning it is produced in the gut in response to eating and works to regulate the metabolic response to food. Specifically, it is secreted by L-cells in the small intestine and colon when nutrients arrive from the stomach.

In its natural form, GLP-1 is broken down extremely quickly by an enzyme called DPP-4 (Dipeptidyl Peptidase-4). Its half-life in the bloodstream is just 1 to 2 minutes. This rapid breakdown means natural GLP-1 acts as a short, sharp signal rather than a sustained influence.

GLP-1 receptor agonists are engineered peptides designed to replicate GLP-1's effects while being resistant to DPP-4 breakdown, giving them a dramatically longer duration of action.

How GLP-1 Controls Appetite

The appetite-suppressing effects of GLP-1 operate through several distinct mechanisms, and understanding them explains why the results can be so striking.

Slowing gastric emptying
GLP-1 reduces the rate at which the stomach empties its contents into the small intestine. When food stays in the stomach longer, the physical sensation of fullness persists longer after a meal. This is one of the most immediate and tangible effects people notice when starting GLP-1 therapy. Meals that previously left them hungry an hour later now keep them satisfied for significantly longer.

Hypothalamic signalling
GLP-1 receptors exist in the hypothalamus, the part of the brain responsible for regulating hunger, satiety, body temperature and energy homeostasis. When GLP-1 activates these receptors, it directly reduces the drive to eat. Many people describe this effect as the background "food noise" quieting down: the near-constant thoughts about food, cravings and urges to snack that many people experience become significantly less intrusive.

Reward pathway modulation
Emerging research suggests GLP-1 also influences the brain's reward pathways, particularly the dopamine-driven responses associated with highly palatable foods. This may explain why many people on GLP-1 therapy report reduced cravings specifically for high-fat, high-sugar foods, not just a general reduction in appetite.

Reducing glucagon secretion
GLP-1 suppresses the release of glucagon from the pancreas. Since glucagon signals the liver to release stored glucose, reducing glucagon levels helps stabilise blood sugar and reduces the sharp spikes and crashes that drive hunger between meals.

How GLP-1 Affects Metabolism

Beyond appetite, GLP-1 has meaningful effects on how the body processes and stores energy.

Insulin sensitivity
GLP-1 enhances insulin secretion in a glucose-dependent manner. Critically, this only happens when blood glucose is elevated, which means it does not drive hypoglycaemia (low blood sugar) the way some older diabetes medications do. Over time, improved insulin dynamics contribute to better metabolic flexibility: the body becomes more efficient at switching between burning glucose and fat for fuel.

Pancreatic beta cell function
Research suggests GLP-1 may have a protective effect on the pancreatic beta cells responsible for insulin production. In type 2 diabetes, these cells are often under significant chronic stress. GLP-1 receptor activation appears to reduce this stress and support cell survival, which is one reason GLP-1 agonists are now frontline treatments for type 2 diabetes.

Adipose tissue effects
At the cellular level, GLP-1 influences how fat cells store and release fat. Reduced glucagon, improved insulin sensitivity and the downstream effects of weight loss itself all contribute to a shift in how the body manages its fat stores over time.

Why the Results Are So Different from Conventional Approaches

Conventional calorie restriction produces weight loss, but it also triggers hormonal counterresponses that work against sustained results. As body weight falls, levels of hunger hormones like ghrelin rise, while satiety hormones like leptin fall. The body effectively fights back against the calorie deficit, making it increasingly difficult to maintain.

GLP-1 receptor agonists do not simply suppress appetite through willpower-dependent mechanisms. They intervene at the hormonal level, modulating the very signals that drive hunger. This is why clinical trial participants are able to maintain significant caloric deficits for extended periods without the same levels of compensatory hunger that typically undermine conventional dieting.

This is also why the weight tends to return when GLP-1 therapy is stopped, particularly without accompanying lifestyle changes. The underlying hormonal environment shifts back, and the drives that led to weight gain reassert themselves. This is not a failure of the compound; it reflects the chronic, biological nature of obesity.

What the Clinical Trials Showed Over Time

The STEP and SURMOUNT trials followed people for more than a year, and their results share a few consistent patterns.

Side effects: Nausea and other gastrointestinal effects were the most common, and they clustered in the early weeks. In every trial the dose was raised gradually under medical supervision, which is how those effects were managed.

The shape of the curve: Most of the weight loss happened in roughly the first six months, after which it slowed and levelled off. Individual results varied widely around the average.

After stopping: In extension studies, much of the weight lost was regained once treatment stopped, which is why the approved medicines are prescribed as long-term treatments rather than courses.

Combining GLP-1 Peptides with Other Compounds

Some protocols combine GLP-1 compounds with other peptides or compounds to address specific goals alongside weight loss. For example:

• BPC-157 or TB-500 may be used to manage any gut discomfort associated with GLP-1 therapy, given their tissue-protective properties
• Growth hormone secretagogues may be used alongside GLP-1 compounds to support lean mass preservation during weight loss
• AOD-9604 or HGH Fragment 176-191 are sometimes considered for their targeted fat mobilisation properties

These combinations are at the more advanced end of peptide protocols and should be approached with appropriate research and, where possible, professional guidance.

Sources

The research, regulatory documents and clinical guidelines behind the claims in this article:

• Holst JJ. The physiology of glucagon-like peptide 1. Physiological Reviews, 2007.
• Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism, 2018.
• van Bloemendaal L, IJzerman RG, et al. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes, 2014.
• Wilding JPH, Batterham RL, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 2021.
• Rubino D, Abrahamsson N, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA, 2021.
• Garvey WT, Batterham RL, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nature Medicine, 2022.

Disclaimer: The information in this article is for educational purposes only. STRIATA peptides are research compounds and are not approved medicines. Always consult a qualified healthcare professional before beginning any protocol.